This site is not current and I have no plans to make it current. The CDSA has become largely irrelevant in my view. It is a relic of the last century, fatally disengaged from the reality of this century.
This site describes the schedules of the Canadian Controlled Drugs and Substances Act (CDSA) up to 2015.
The CDSA is the federal legislation that spells out which chemicals and plants Canadian citizens may not grow, buy, sell, swallow, hold, or otherwise lust after.
If you do grow, buy, sell, swallow, hold, or otherwise lust after any of these chemicals or plants you may be arrested, fined, jailed, or all three.
Also described here are the United Kingdom Misuse of Drugs Act (MDA), the United Nations Drugs and Substances under International Control, the United States Controlled Substances Act (CSA), and substances controlled by the European Union.
Controlled Drugs and Substances Act
Controlled Substances Act
- 14 Dec 2015 Final rule 80 FR 69861: Eluxadoline; Placement into Schedule IV.
- 13 Nov 2015 Final rule 80 FR 70657: Three Synthetic Phenethylamines [25B-NBOMe, 25C-NBOMe, 25I-NBOMe]; Extension of Temporary Placement in Schedule I.
- 13 Nov 2015 Proposed rule 80 FR 70649: Three Synthetic Phenethylamines [25B-NBOMe, 25C-NBOMe, 25I-NBOMe]; Placement into Schedule I.
- 16 Sep 2015 Proposed rule 80 FR 55565: Synthetic Cannabinoid MAB-CHMINACA; Temporary Placement into Schedule I.
- 11 Sep 2015 Final rule 80 FR 54715: [123I]Ioflupane; Removal from Schedule II.
- 17 Jul 2015 Final rule 80 FR 42381: Temporary Placement of Acetyl Fentanyl into Schedule I.
- 15 May 2015 Final rule 80 FR 27854: Extension of Temporary Placement of UR-144, XLR11, and AKB48 in Schedule I.
- 14 May 2015 Proposed rule 80 FR 27611: Placement of UR-144, XLR11, and AKB48 Into Schedule I.
- 20 Mar 2015 Final rule 80 FR 14842: Substances Temporarily Controlled Under Schedule I. A bit of Schedule I Section (h) housekeeping. Technical amendments, not substantive changes.
- 30 Jan 2015 Final rule 80 FR 5042: Temporary Placement of Three Synthetic Cannabinoids [UR-144, XLR11, AKB48] Into Schedule I.
- 23 Jan 2015 Final rule 80 FR 3468: Removal of Naloxegol From Control.
- 18 Dec 2014 Act of Congress H.R. 4771, 113 Cong., 2nd Sess.: Designer Anabolic Steroid Control Act of 2014. Bill H.R. 4771 redefines “anabolic steroid,” greatly expanding the reach of the CSA. This new definition is similar in spirit to the Analogue Act, which expanded the scope of Schedules I and II to include “substantially similar” substances.
- 29 Sep 2014 Final rule 79 FR 51243: Placement of Suvorexant into Schedule IV.
- 06 Oct 2014 Final rule 79 FR 49661: Rescheduling of Hydrocodone Combination Products From Schedule III to Schedule II.
- 29 Sep 2014 Final rule 79 FR 51243: Placement of Suvorexant into Schedule IV.
- 14 Aug 2014 Final rule 79 FR 37623: Placement of Tramadol Into Schedule IV.
- 31 Mar 2014 Final rule 79 FR 10985: Placement of Alfaxalone into Schedule IV.
- 07 Mar 2014 Final rule 79 FR 12938: Temporary Placement of 10 Synthetic Cathinones [4-MEC, 4-MePPP, α-PVP, Butylone, Pentedrone, Pentylone, 4-FMC, 3-FMC, Naphyrone, α-PBP] Into Schedule I.
- 10 Feb 2014 Final rule 79 FR 7577: Temporary Placement of Four Synthetic Cannabinoids [PB-22, 5F-PB-22, AB-FUBINACA, ADB-PINACA] Into Schedule I.
- 02 Dec 2013 Final rule 78 FR 72013: Placement of Perampanel into Schedule III.
- 16 May 2013 Final rule 78 FR 28735: Temporary Placement of Three Synthetic Cannabinoids [UR-144, 5F-UR-144 (XLR11), APINACA (AKB48)] Into Schedule I.
- 07 Jun 2013 Final rule 78 FR 26701: Placement of Lorcaserin Into Schedule IV.
- 12 Apr 2013 Final rule 78 FR 21818: Placement of Methylone Into Schedule I.
Drugs and Substances under International Control
Substances Controlled by the European Union
- Includes proposal of 25 June 2013 for a Council Decision on submitting 5-(2-aminopropyl)indole (5-IT) to control measures.
Readings on drug law design and policy—the good, the bad, and the unworkable.
- Hudson AL, Lalies MD, Baker GB, Wells K, Aitchison KJ (2014).
Ecstasy, Legal Highs and Designer Drug Use: A Canadian Perspective. Drug Science, Policy and Law, 1. http://dx.doi.org/10.1177/2050324513509190
- DeBeck K, Wood E, Montaner J, Kerr T. (2009).
Canada’s New Federal “National Anti-Drug Strategy”: An Informal Audit of Reported Funding Allocation International Journal of Drug Policy 28: 188–191. http://dx.doi.org/10.1016/j.drugpo.2008.04.004
- Wood E, Kerr T, Tyndall MW, Montaner JSG. (2008).
The Canadian government’s treatment of scientific process and evidence: Inside the evaluation of North America’s first supervised injecting facility International Journal of Drug Policy 19: 220–225. http://dx.doi.org/10.1016/j.drugpo.2007.11.001
- Wodak A (2008).
Going Soft on Evidence and Due Process: Canada Adopts US Style Harm Maximization International Journal of Drug Policy 19: 226–228. http://dx.doi.org/10.1016/j.drugpo.2008.02.008
- Phillips GF (1967).
Some chemical aspects of drug legislation. Science & Justice 7: 17-30. http://dx.doi.org/10.1016/S0015-7368(67)70367-9
- King LA (2009).
Forensic chemistry of substance misuse: a guide to drug control. Cambridge, UK: Royal Society of Chemistry. 249 p.
- King LA (2013).
Chapter 1 - Legal Classification of Novel Psychoactive Substances: An International Comparison. In: Dargan PI, Wood DM, editors. Novel Psychoactive Substances. Boston: Academic Press. pp. 3–27. http://dx.doi.org/10.1016/B978-0-12-415816-0.00001-8
- King LA (2013).
Legal controls on cannabimimetics: An international dilemma? Drug Testing and Analysis: 6: 80-87. http://dx.doi.org/10/1002/dta.1510
- King LA, Ujváry I, Brandt SD (2013).
Drug laws and the “derivative” problem Drug Testing and Analysis. http://dx.doi.org/10.1002/dta.1523
- Nutt DJ, King LA, Nichols DE (2013).
Effects of Schedule I drug laws on neuroscience research and treatment innovation. Nature Reviews Neuroscience 14: 577–585. http://dx.doi.org/10.1038/nrn3530
- ForensicToxGuy (2013).
Analogue or not an analogue: that is the question! The Dose Makes The Poison—the incessant ramblings of a forensic toxicologist and drug chemist.
This website is provided for general information purposes only. It is not intended to replace official versions of legislation. It is not meant as legal or other professional advice. If you require specific legal advice on any issue, please consult a lawyer. The information here is presented without warranty, either expressed or implied, as to its accuracy, timeliness, or completeness.
· Isomer Design
